NDLI: Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals.

Please wait, while we are loading the content...

Year: 2017 Volume: 16

Year: 2016 Volume: 15

Year: 2015 Volume: 14

Year: 2014 Volume: 13

Year: 2013 Volume: 12

Year: 2013 Volume: 12 Issue: 6

Year: 2013 Volume: 12 Issue: 5

Year: 2013 Volume: 12 Issue: 4

Year: 2013 Volume: 12 Issue: 3

Year: 2013 Volume: 12 Issue: 2

Year: 2013 Volume: 12 Issue: 1

Stigma and access to HIV care among HIV-infected women in Kolkata, West Bengal.

A comparative study of oral candidal carriage and its association with CD4 count between HIV-positive and healthy individuals.

A model for reduced HIV-1 viral load monitoring in resource-limited settings.

Impact of antiretroviral therapy on glycemia and transaminase levels in patients living with HIV/AIDS in Limbe, Cameroon.

HIV risk assessment and risk reduction strategies in the context of prevailing gender norms in rural areas of Cabo Delgado, Mozambique.

Barriers to retention in care as perceived by persons living with HIV in rural Ethiopia: focus group results and recommended strategies.

Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India.

Antiretroviral therapy protects against frailty in HIV-1 infection.

More than 20 years of research into the quality of life of people with HIV and AIDS--a descriptive review of study characteristics and methodological approaches of published empirical studies.

Outcome of HCV genotype 1 treatment in HIV-coinfected patients with chronic kidney disease.

Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals.

Frequent coinfection with hepatitis among HIV-positive patients in Urumqi, China.

Achieving improvements across the HIV treatment cascade: a clinical management algorithm based on IAPAC's entry into and retention in care and antiretroviral therapy adherence guidelines.

Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Babiker, Zahir Osman Eltahir Douthwaite, Sam Thomas Collier, Lucy Elizabeth Pennell, Ashley Uriel, Alison J. Wilkins, Edmund
Description	Country affiliation: United kingdom Author Affiliation: Babiker ZO ( Monsall Unit, North Manchester General Hospital, Manchester, UK.)
Abstract	PURPOSE: The use of maraviroc in our unit was reviewed with regard to efficacy and safety and also reviewed with regard to how our experience reflects the data presented in clinical trials. METHODS: We utilized the pharmacy dispensary system to identify any patient dispensed maraviroc and conducted a case note review. RESULTS: We identified 27 patients who have been prescribed maraviroc as part of their antiretroviral treatment. In all, 81% were men and 81% were white British. There were 26 treatment-experienced patients and 1 treatment-naive patient. At the time of switching to maraviroc, 17 patients had detectable HIV viral loads and 10 had HIV RNA levels <40 copies/mL. At completion, 6 undetectable patients maintained undetectability and 10 viremically detectable patients achieved viral suppression. Maraviroc was discontinued in 18.5% of patients and the only adverse drug reaction reported was a rash. CONCLUSIONS: The experience of using maraviroc by our study participants shows similarity in terms of efficacy and safety to the MERIT and MOTIVATE clinical trials.
File Format	HTM / HTML
ISSN	23259582
Issue Number	1
Volume Number	12
e-ISSN	23259582
Journal	Journal of the International Association of Providers of AIDS Care (JIAPAC)
Language	English
Publisher	Sage Publications
Publisher Date	2013-01-01
Publisher Place	United States
Access Restriction	Subscribed
Subject Keyword	Discipline Acquired Immunodeficiency Syndrome Cyclohexanes Therapeutic Use Hiv Fusion Inhibitors Hiv Infections Drug Therapy Triazoles Adult Cd4 Lymphocyte Count Drug Hypersensitivity Drug Therapy, Combination Exanthema Chemically Induced Female Hiv-1 Genetics Humans Male Middle Aged Rna, Viral Blood Retrospective Studies Viral Load Young Adult Journal Article
Content Type	Text
Resource Type	Article
Subject	Infectious Diseases Immunology Dermatology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in